International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH); Draft Guidance for Industry on Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Comparative Metabolism Studies in Laboratory Animals (VICH GL47); Availability, 18507-18508 [2010-8229]

Agencies

• Food and Drug Administration
• DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 75, Number 69 (Monday, April 12, 2010)]
[Notices]
[Pages 18507-18508]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-8229]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-D-0164]


International Cooperation on Harmonisation of Technical 
Requirements for Registration of Veterinary Medicinal Products (VICH); 
Draft Guidance for Industry on Studies to Evaluate the Metabolism and 
Residue Kinetics of Veterinary Drugs in Food-Producing Animals: 
Comparative Metabolism Studies in Laboratory Animals (VICH GL47); 
Availability

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Notice.

-----------------------------------------------------------------------

SUMMARY:  The Food and Drug Administration (FDA) is announcing the 
availability of a draft guidance for industry (206) entitled 
``Draft Guidance for Industry on Studies to Evaluate the Metabolism and 
Residue Kinetics of Veterinary Drugs in Food-Producing Animals: 
Comparative Metabolism Studies in Laboratory Animals,'' VICH GL47. This 
draft guidance has been developed for veterinary use by the 
International Cooperation on Harmonisation of Technical Requirements 
for Registration of Veterinary Medicinal Products (VICH). This draft 
VICH guidance document is intended to provide recommendations for 
internationally harmonized procedures to identify the metabolites of 
veterinary food animal drugs in laboratory animals used for 
toxicological testing for the purpose of comparison to the residues of 
the drugs in food animals.

DATES: Although you can comment on any guidance at any time (see 21 CFR 
10.115(g)(5)), to ensure that the agency considers your comment on this 
draft guidance before it begins work on the final version of the 
guidance, submit written or electronic comments on the draft guidance 
by May 12, 2010.

ADDRESSES: Submit written requests for single copies of the draft 
guidance to the Communications Staff (HFV-12), Center for Veterinary 
Medicine, Food and Drug Administration, 7519 Standish Pl., Rockville, 
MD 20855. Send one self-addressed adhesive label to assist that office 
in processing your request.
    Submit written comments on the draft guidance to the Division of 
Dockets Management (HFA-305), Food and Drug Administration, 5630 
Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments 
to https://www.regulations.gov. See the SUPPLEMENTARY INFORMATION 
section for electronic access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT: Julia Oriani, Center for Veterinary 
Medicine (HFV-151), Food and Drug Administration, 7500 Standish Pl., 
Rockville, MD 20855, 240-276-8204, e-mail: julia.oriani@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Background

    FDA is announcing the availability of a draft guidance for industry 
(206) entitled ``Draft Guidance for Industry on Studies to 
Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in 
Food-Producing Animals: Comparative Metabolism Studies in Laboratory 
Animals,'' VICH GL47. In recent years, many important initiatives have 
been undertaken by regulatory authorities and industry associations to 
promote the international harmonization of regulatory requirements. FDA 
has participated in efforts to enhance harmonization and has expressed 
its commitment to seek scientifically based harmonized technical 
procedures for the development of pharmaceutical products. One of the 
goals of harmonization is to identify and then reduce differences in 
technical requirements for drug development among regulatory agencies 
in different countries.
    FDA has actively participated in the International Conference on 
Harmonisation of Technical Requirements for Approval of Pharmaceuticals 
for Human Use for several years to develop harmonized technical 
requirements for the approval of human pharmaceutical and biological 
products among the European Union (EU), Japan, and the United States. 
The VICH is a parallel initiative for veterinary medicinal products. 
The VICH is concerned with developing harmonized technical requirements 
for the approval of veterinary medicinal products in the EU, Japan, and 
the United States, and includes input from both regulatory and industry 
representatives.
    The VICH Steering Committee is composed of member representatives 
from the European Commission, European Medicines Evaluation Agency, 
European Federation of Animal Health, Committee on Veterinary Medicinal 
Products, the U.S. FDA, the U.S. Department of Agriculture, the Animal 
Health Institute, the Japanese Veterinary Pharmaceutical Association, 
the Japanese Association of Veterinary Biologics, and the Japanese 
Ministry of Agriculture, Forestry, and Fisheries.
    Four observers are eligible to participate in the VICH Steering 
Committee: One representative from the government of Australia/New 
Zealand, one representative from the industry in Australia/New Zealand, 
one representative from the government of Canada, and one 
representative from the industry of Canada. The VICH Secretariat, which 
coordinates the preparation of documentation, is provided by the 
International Federation for Animal Health (IFAH). An IFAH 
representative also participates in the VICH Steering Committee 
meetings.

II. Draft Guidance on Studies to Evaluate the Metabolism and Residue 
Kinetics of Veterinary Drugs in Food-Producing Animals

    The VICH Steering Committee held a meeting on November 5, 2009, and 
agreed that the draft guidance document entitled ``Draft Guidance for 
Industry on Studies to Evaluate the Metabolism and Residue Kinetics of 
Veterinary Drugs in Food-Producing Animals: Comparative Metabolism 
Studies in Laboratory Animals,'' VICH GL47 should be made available for 
public comment. This draft VICH guidance document is one of a series 
developed to facilitate the mutual acceptance of residue chemistry data 
for veterinary drugs used in food-producing animals. This guidance was 
prepared after consideration of the current requirements for evaluating 
veterinary drug residues in the EU, Japan, United States, Australia, 
New Zealand and Canada.
    The objective of this guidance is to provide recommendations for 
internationally harmonized procedures to identify the metabolites of 
veterinary food animal drugs in laboratory animals used for 
toxicological testing for the purpose of comparison to the residues of 
the drugs in food animals. The purpose of comparative metabolism 
studies is to determine if laboratory animals used for toxicological 
testing have been exposed to the metabolites that humans will be 
exposed to as residues in products of food animal origin.
    The human food safety evaluation of veterinary drug residues 
assures that food derived from treated animals is

[[Page 18508]]

safe for human consumption. As part of the data collection process, 
studies are conducted to characterize the metabolites to which 
laboratory animals are auto-exposed during the toxicological testing of 
the veterinary drug. The purpose of these studies is to determine 
whether the metabolites that people will consume from tissues of target 
food animals are also produced by metabolism in the laboratory animals 
used for the safety testing.
    FDA and the VICH Expert Working Group will consider comments about 
the draft guidance document.

III. Significance of Guidance

    This draft guidance, developed under the VICH process, has been 
revised to conform to FDA's good guidance practices regulation (21 CFR 
10.115). For example, the document has been designated ``guidance'' 
rather than ``guideline.'' In addition, guidance documents must not 
include mandatory language such as ``shall,'' ``must,'' ``require,'' or 
``requirement,'' unless FDA is using these words to describe a 
statutory or regulatory requirement.
    The draft guidance, when finalized, will represent the agency's 
current thinking on this topic. It does not create or confer any rights 
for or on any person and does not operate to bind FDA or the public. An 
alternative approach may be used if such approach satisfies the 
requirements of applicable statutes and regulations.

IV. Paperwork Reduction Act of 1995

    This draft guidance refers to previously approved collections of 
information found in FDA regulations. These collections of information 
are subject to review by the Office of Management and Budget (OMB) 
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The 
collections of information in sections 1-3 of this guidance have been 
approved under OMB control no. 0910-0032.

V. Comments

    Interested persons may submit to the Division of Dockets Management 
(see ADDRESSES) written or electronic comments regarding this document. 
Submit a single copy of electronic comments or two paper copies of any 
mailed comments, except that individuals may submit one paper copy. 
Comments are to be identified with the docket number found in brackets 
in the heading of this document. Received comments may be seen in the 
Division of Dockets Management between 9 a.m. and 4 p.m., Monday 
through Friday.

VI. Electronic Access

    Persons with access to the Internet may obtain the draft guidance 
at either https://www.fda.gov/AnimalVeterinary/default.htm or https://www.regulations.gov.

    Dated: April 6, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-8229 Filed 4-9-10; 8:45 am]
BILLING CODE 4160-01-S